A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome
Status:
Recruiting
Trial end date:
2023-03-05
Target enrollment:
Participant gender:
Summary
The aims of the study are:
- to learn if soticlestat, when given as add-on therapy, reduces the number of major motor
drop seizures in children, teenagers, and adults with Lennox-Gastaut Syndrome.
- to assess the safety profile of soticlestat when given in combination with other
therapies.
Participants will receive their standard anti-seizure therapy, plus either tablets of
soticlestat or placebo. A placebo looks just like soticlestat but will not have any medicine
in it. Participants will take soticlestat or placebo for 16 weeks, followed by a gradual dose
reduction for 1 week. Then, participants will be followed up for 2 weeks.